UK markets closed
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • FTSE 250

    20,596.91
    -196.81 (-0.95%)
     
  • AIM

    1,195.31
    -2.78 (-0.23%)
     
  • GBP/EUR

    1.1239
    -0.0042 (-0.37%)
     
  • GBP/USD

    1.3684
    -0.0046 (-0.34%)
     
  • BTC-GBP

    24,309.67
    +529.58 (+2.23%)
     
  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     
  • S&P 500

    3,841.47
    -11.60 (-0.30%)
     
  • DOW

    30,996.98
    -179.03 (-0.57%)
     
  • CRUDE OIL

    51.98
    -1.15 (-2.16%)
     
  • GOLD FUTURES

    1,855.50
    -10.40 (-0.56%)
     
  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     
  • HANG SENG

    29,447.85
    -479.91 (-1.60%)
     
  • DAX

    13,873.97
    -32.70 (-0.24%)
     
  • CAC 40

    5,559.57
    -31.22 (-0.56%)
     

Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors

Evaxion Biotech
·2-min read

COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.

The open label, multi-center study will assess the safety, tolerability, pharmacodynamic response and efficacy of EVX-02 with checkpoint inhibitors in patients who have had a complete resection of Stage IIIB/IIIC/IIID or Stage IV melanoma and are at high risk of recurrence. The study is planned to take place at five clinical centers in Australia, targeting recruitment of a total of 46 patients. Early data read out from this Phase I/IIa is expected in H1 2021.

Lars Wegner, CEO of Evaxion Biotech, said: “We are very excited to start this Phase I/IIa study with EVX-02 further demonstrating the potential of Evaxion’s integrated PIONEER™ artificial intelligence platform to accelerate the discovery and development of a new generation of patient-specific cancer immunotherapies. We believe that the computational power behind the discovery of this compound shows that EVX-02 may have the potential to make a difference in malignant melanoma, which accounts for 1% of skin tumors and causes of 60% mortality due to skin cancers.”

EVX-02 is a personalized cancer immunotherapy designed based on the unique tumor genetic fingerprint of each individual patient and consists of patient-specific cancer neoepitopes incorporated into a DNA plasmid. The mutanome immunotherapy is devised by PIONEER, Evaxion’s computational platform which has been shown to be capable of identifying cancer neoepitopes from matched tumor-normal DNA sequencing data and ranking of the neoepitopes according to their predicted capability in stimulating a T-cell response.

The aim of EVX-02 is to promote T cell priming and expansion of effector cells for direct tumor killing. When administered, EVX-02 is taken up by antigen presenting cells and the neoepitopes are then expressed and displayed on the cell surface, thus triggering a neoepitope-specific immune response targeting the cancer cells.

About Evaxion
Evaxion Biotech A/S is a clinical stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections.

For more information

Evaxion Biotech

LifeSci Advisors LLC

Glenn S. Vraniak

Mary-Ann Chang

Chief Financial Officer

Managing Director

gvr@evaxion-biotech.com

mchang@lifesciadvisors.com

t: +1 (513) 476-2669

+44 7483 284 853